Elias Björnson, University of Gothenburg, Sweden, discusses data from a UK Biobank Study which investigated the association between triglyceride-rich lipoproteins/remnant cholesterol and risk of coronary heart disease, and the atherogenicity of those particles compared to low-density lipoprotein particles.
NICU babies need targeted TG monitoring
Premature babies receiving TG containing nutrition in neonatal intensive care units (NICU) need individualised TG monitoring, according to researchers who compared TG levels in neonates stratified by gestational age (GA), birth weight (BW), and growth restriction status. From 2018 to 2021, 427 infants born at <32 weeks GA or with BW <1,500 gm were included […]
Fresh support for remnant cholesterol measurement and management
Results of two recent studies linking elevated remnant cholesterol (RC) to premature mortality and atherosclerotic cardiovascular disease (ASCVD) have raised the question of whether RC should be included in risk stratification and as a treatment target.
Evinacumab in children with HoFH: What’s the evidence?
Dr Eliot Brinton discusses the unmet need for new treatments for children with homozygous familial hypercholesterolaemia (HoFH), and results of recent studies of evinacumab in children with HoFH aged 5-11 years and in those aged 12-17 years.
The SHASTA-2 trial: What the results mean for clinicians
Professor Daniel Gaudet, University of Montreal, Canada describes the results of the Phase 2b, SHASTA-2 dose-finding trial of plozasiran 10 mg, 25 mg or 50 mg s.c. or matched placebo in patients with severe hypertriglyceridaemia, and discusses what the findings mean for clinicians.
Phase 3 evinacumab data show efficacy in children with HoFH aged 5-11 years
Evinacumab reduces lipid levels in children with HoFH aged 5-11 years with LDL-C >130 mg/dL (3.4 mmol/L) despite optimised lipid lowering therapy (LLT), according to results of a Phase 3 open label study published in Circulation. In the study of 14 patients, 5-11 years of age with genetically proven HoFH (true homozygotes and compound heterozygotes), […]
